Vivos Inc (RDGL) stock
Close on Oct 19, 2026Market cap $23.44MP/E –Yield –
Vivos Inc grew revenue 91.5% to $99.10K over the twelve months to Jun 30, 2026. Free cash flow was -$2.16M. At the latest close the market valued the company at $23.44M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $23.44M
- P/E ratio
- –
- Price to sales
- 236.54
- Price to book
- 8.51
- Dividend yield
- –
- Free cash flow yield
- -9.22%
Fundamentals
- Revenue
- $99.10K
- Net income
- -$3.60M
- EPS, diluted
- $0.00
- Free cash flow
- -$2.16M
- Book value per share
- $0.01
- Diluted shares
- 491M
Trading
- Previous close
- $0.05
- Open
- $0.05
- Day's range
- $0.04 – $0.05
- Volume
- 1,188,035
- Average volume (20 days)
- 921,550
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | RDGL | S&P 500 | Difference | RDGL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.2% | +0.6% | −1.9 pts | ||
| 3 months | -20.3% | +3.4% | −23.6 pts | ||
| Year to date | -30.7% | +13.3% | −43.9 pts | ||
| 1 year | -37.6% | +16.6% | −54.2 pts | ||
| 3 years | -12.5% | +86.4% | −98.9 pts | -4.4% | +23.1% |
| 5 years | -55.2% | +81.9% | −137.0 pts | -14.8% | +12.7% |
| 10 years | -96.1% | +318.9% | −415.0 pts | -27.8% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vivos filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
About Vivos
Surgical & Medical Instruments & Apparatus
Vivos Inc. is a radiation oncology medical device company focused on developing precision radionuclide therapy products. Its core technologies utilize yttrium-90 (Y-90) and include RadioGel for treating solid tumors and positive surgical margins in humans, alongside IsoPet for targeting solid tumors in veterinary patients. The company operates through human and animal therapy divisions, with the latter providing direct treatments and clinic certifications. It also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel platform designed for delivering active pharmaceutical ingredients and therapeutic agents.
Company profile, executives and historyVivos stock: common questions
What is Vivos's stock price?
RDGL closed at $0.05 on Oct 19, 2026, down 2.51% on the day.
What is Vivos's market cap?
Vivos was worth $23.44M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is RDGL's P/E ratio?
Vivos lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Vivos make?
Vivos reported revenue of $99.10K for the twelve months to Jun 30, 2026, up 91.5% from a year earlier.
Does Vivos pay a dividend?
No. Vivos has not paid a cash dividend over the last twelve months.
How has RDGL stock performed over the past year?
Including dividends, RDGL returned -37.6% over the past year, against +16.6% for the S&P 500.
Who are Vivos's competitors?
Companies most similar to Vivos by business, industry and size include PAVM, GUTS, PFSA, GIPL, PETV.
See a number that looks wrong?